Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Mirza on the Impact of PARP Inhibitors in Ovarian Cancer

April 2nd 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the impact of PARP inhibitors in ovarian cancer.

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

March 29th 2018

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Frontline Pembrolizumab Plus Chemo Shows Promise in Ovarian Cancer

March 28th 2018

First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Similar Efficacy Across PARP Inhibitors in Ovarian Cancer, But Safety Analysis Favors Olaparib

March 28th 2018

Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.

Olaparib/Durvalumab Combo Active in Relapsed Ovarian Cancer

March 27th 2018

Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.

Pembrolizumab Plus Niraparib Shows Promise in Ovarian Cancer

March 27th 2018

Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).

Pembrolizumab Plus Mirvetuximab Soravtansine Active in Ovarian Cancer

March 27th 2018

Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.

Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian Cancer

March 26th 2018

Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

March 26th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer

March 26th 2018

To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.

Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight

March 26th 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Low Body Weight, Platelet Counts Predict Niraparib Dose Reductions for Ovarian Cancer

March 25th 2018

Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Monk on Choosing Between PARP Inhibitors in Ovarian Cancer

March 25th 2018

Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Checkpoint Inhibitors Induce Higher Rate of Adverse Events in Recurrent Ovarian Cancer

March 25th 2018

The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.

Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian Cancer

March 23rd 2018

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. O'Malley Discusses PARP Combinations in Ovarian Cancer

March 19th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.

Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer

March 16th 2018

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses challenges with immunotherapy agents in the treatment of patients with ovarian cancer.

Dr. Crane on the Toxicity Profile of Combinations for Ovarian Cancer

March 13th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the toxicity profile of combination regimens for patients with ovarian cancer.

Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian Cancer

March 9th 2018

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

Dr. O'Malley on the Tolerability of PARP Inhibitors in Ovarian Cancer

February 28th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.